Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291532 | 0.86 | CHEK1 (0.75) | CHEK1MCL1KDM4E | |
| SCHEMBL4300788 | 0.83 | CHEK1 (1.00) | CHEK1MCL1AHRNR4A2 | |
| SCHEMBL13659542 | 0.82 | CHEK1 (0.70) | CHEK1MCL1KDM4EALDH1A1DYRK1A | |
| SCHEMBL4294012 | 0.81 | CHEK1 (0.67) | CHEK1MCL1 | |
| SCHEMBL4295676 | 0.78 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL4298767 | 0.78 | CHEK1 (0.90) | CHEK1MCL1AHRNR4A2 | |
| SCHEMBL4296798 | 0.76 | CHEK1 (1.00) | CHEK1ALDH1A1F7LTA4HF3 | |
| SCHEMBL4287417 | 0.75 | CHEK1 (0.64) | CHEK1 | |
| SCHEMBL4287289 | 0.75 | CHEK1 (0.60) | CHEK1KDM4E | |
| SCHEMBL4296686 | 0.75 | CHEK1 (0.73) | CHEK1KDM4EGPR35ALDH1A1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | claimed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885MCL1 343/4885KDM4E 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.